Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: An Open-Label Randomized Phase III Trial of BMS-936558 (Nivolumab) Versus Docetaxel in Previously Treated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)
Brief Summary: The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy


Options:
A: Arm Label: Monotherapy; Type: EXPERIMENTAL; Interventions: Biological: MEDI4736 (Durvalumab) | Arm Label: Combination Therapy; Type: EXPERIMENTAL; Interventions: Biological: MEDI4736 (Durvalumab)+Tremelimumab, Biological: Tremelimumab | Arm Label: Standard of Care; Type: ACTIVE_COMPARATOR; Interventions: Drug: Paclitaxel + Carboplatin, Drug: Gemcitabine + Cisplatin, Drug: Gemcitabine + Carboplatin, Drug: Pemetrexed + Cisplatin, Drug: Pemetrexed + Carboplatin | Intervention Type: BIOLOGICAL; Name: MEDI4736 (Durvalumab); Assigned to Arm(s): Monotherapy | Intervention Type: BIOLOGICAL; Name: MEDI4736 (Durvalumab)+Tremelimumab; Assigned to Arm(s): Combination Therapy | Intervention Type: DRUG; Name: Paclitaxel + Carboplatin; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Gemcitabine + Cisplatin; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Gemcitabine + Carboplatin; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Pemetrexed + Cisplatin; Assigned to Arm(s): Standard of Care | Intervention Type: DRUG; Name: Pemetrexed + Carboplatin; Assigned to Arm(s): Standard of Care | Intervention Type: BIOLOGICAL; Name: Tremelimumab; Assigned to Arm(s): Combination Therapy
B: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: EXPERIMENTAL; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel
C: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab | Arm Label: Arm B: Nivolumab + Ipilimumab; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Ipilimumab | Arm Label: Arm C: Nivolumab + Platinum doublet chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Nivolumab, Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed, Drug: Paclitaxel | Arm Label: Arm D: Platinum doublet chemotherapy; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Cisplatin, Drug: Gemcitabine, Drug: Pemetrexed, Drug: Paclitaxel | Intervention Type: DRUG; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab, Arm B: Nivolumab + Ipilimumab, Arm C: Nivolumab + Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Ipilimumab; Assigned to Arm(s): Arm B: Nivolumab + Ipilimumab | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Cisplatin; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Pemetrexed; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm C: Nivolumab + Platinum doublet chemotherapy, Arm D: Platinum doublet chemotherapy
D: Arm Label: Arm A: Nivolumab; Type: EXPERIMENTAL; Interventions: Biological: Nivolumab | Arm Label: Arm B: Docetaxel; Type: ACTIVE_COMPARATOR; Interventions: Drug: Docetaxel | Intervention Type: BIOLOGICAL; Name: Nivolumab; Assigned to Arm(s): Arm A: Nivolumab | Intervention Type: DRUG; Name: Docetaxel; Assigned to Arm(s): Arm B: Docetaxel

Answer: D